Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Oncologists in Italy(?)

Council Members in this Study Group: 85

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Rossana Berardi, MD
Consultant Medical Oncologist
Università Politecnica delle Marche

Rossana Berardi, MD, is a Researcher and Lecturer - Consultant Medical Oncologist in the Department of Medical Oncology at the Universita Politecnica delle Marche, Italy, since November 2005. She is involved in clinical research and GCP trials on the treatment of solid tumors in particular on gastrointestinal...

Federica Bertolini, MD
Medical Oncologist and Researcher
Università di Modena e Reggio Emilia

Federica Bertolini, MD, is a Medical Oncologist and Researcher in the Division of GI Medical Oncology at Policlinico di Modena at the University Of Modena and Reggio Emilia. Dr. Bertolini has expertise in treatment of all gastro-intestinal tumors such as colorectal cancer or pancreatic cancer and is...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Hepcidine is a key regulator of iron balence. Despite the availability of some iron makers (ferritin, sideremia and transferrin), hepcidine dosage can aid in the interpretation of complex clinical cases. However, its use could be limited to very particular clinical cases.

  The FLEX trial, a randomized phase 3 study comparing cisplatin-vinorelbine versus the same regimen plus cetuximab, recently showed that the addition of the monoclonal antibody to chemotherapy significantly prolong survival in chemonaive NSCLC. Several aspects could limit the wide use...

Analysis of: Molecular Testing for Respiratory Viruses | www.aacc.org

RSV infection is very difficult to confirm. In my hospital we use molecular determination of RSV genome from nasal secretions. This approach is expensive, time consuming and it does not offer a quick diagnosis. We treat mainly onco-hematological patients, who are at high risk of RSV infection. In the...

Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com

undefined The cardiomyocyte is highly sensitive to perturbations in energy generation, largely because of its huge energy demani (Force, Nat Rev Cancer 2007). Mitochondrial dysfunction and energy depletion seem to be a common theme in cardiotoxicity. However, unlike in anthracycline cardiotoxicity,...

This trial demonstrated for the first time that adding docetaxel to cisplatin and 5Fluorouracil improves response rate, time to progression and overall survival in head and neck cancer patients with stage III and IV without distant metasteses. This improvement has a price: Grade 3 or 4 leukopenia and...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Professor

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880